Morgan Stanley’s Crinetics Pharmaceuticals CRNX Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$21.9M Buy
760,022
+245,338
+48% +$7.06M ﹤0.01% 2707
2025
Q1
$17.3M Buy
514,684
+9,644
+2% +$323K ﹤0.01% 2846
2024
Q4
$25.8M Sell
505,040
-160,559
-24% -$8.21M ﹤0.01% 2510
2024
Q3
$34M Sell
665,599
-173,026
-21% -$8.84M ﹤0.01% 2239
2024
Q2
$37.6M Buy
838,625
+226,425
+37% +$10.1M ﹤0.01% 2020
2024
Q1
$28.7M Sell
612,200
-684,302
-53% -$32M ﹤0.01% 2298
2023
Q4
$46.1M Buy
1,296,502
+785,181
+154% +$27.9M ﹤0.01% 2546
2023
Q3
$15.2M Sell
511,321
-234,838
-31% -$6.98M ﹤0.01% 2737
2023
Q2
$13.4M Buy
746,159
+93,243
+14% +$1.68M ﹤0.01% 2883
2023
Q1
$10.5M Buy
652,916
+500,328
+328% +$8.04M ﹤0.01% 3098
2022
Q4
$2.79M Buy
152,588
+50,556
+50% +$925K ﹤0.01% 4232
2022
Q3
$2M Sell
102,032
-37,584
-27% -$738K ﹤0.01% 4434
2022
Q2
$2.61M Buy
139,616
+44,326
+47% +$827K ﹤0.01% 4332
2022
Q1
$2.09M Buy
95,290
+57,312
+151% +$1.26M ﹤0.01% 4491
2021
Q4
$1.08M Sell
37,978
-30,976
-45% -$880K ﹤0.01% 5015
2021
Q3
$1.45M Sell
68,954
-113,043
-62% -$2.38M ﹤0.01% 4808
2021
Q2
$3.43M Sell
181,997
-18,756
-9% -$353K ﹤0.01% 4163
2021
Q1
$3.07M Buy
200,753
+15,011
+8% +$229K ﹤0.01% 3904
2020
Q4
$2.62M Buy
185,742
+145,036
+356% +$2.05M ﹤0.01% 3916
2020
Q3
$638K Sell
40,706
-173,115
-81% -$2.71M ﹤0.01% 4507
2020
Q2
$3.75M Buy
213,821
+211,570
+9,399% +$3.71M ﹤0.01% 2968
2020
Q1
$34K Sell
2,251
-15,156
-87% -$229K ﹤0.01% 5596
2019
Q4
$437K Sell
17,407
-131
-0.7% -$3.29K ﹤0.01% 4997
2019
Q3
$264K Buy
17,538
+16,249
+1,261% +$245K ﹤0.01% 4994
2019
Q2
$32K Sell
1,289
-1,693
-57% -$42K ﹤0.01% 5776
2019
Q1
$67K Sell
2,982
-9,201
-76% -$207K ﹤0.01% 5543
2018
Q4
$365K Sell
12,183
-153
-1% -$4.58K ﹤0.01% 4993
2018
Q3
$353K Buy
+12,336
New +$353K ﹤0.01% 5182